Lobbying Relationship

Client

SPARK THERAPEUTICS, INC.

More records

Lobbying firm

SPARK THERAPEUTICS, INC.

More records

  • H.R. 2666 - MVP Act, all provisions. Issues related to the implementation of the CMMI demonstration on Gene Therapy.
  • Issues related to gene therapy and rare diseases.

Duration: to

General Issues: Medicare/Medicaid, Health Issues, Pharmacy

Spending: about $5,390,000 (But it's complicated. Here's why.)

Agencies lobbied since 2017: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Office of the Vice President of the United States

Bills mentioned

H.R.2430: FDA Reauthorization Act of 2017

Sponsor: Greg Walden (R-Ore.)

S.934: FDA Reauthorization Act of 2017

Sponsor: Lamar Alexander (R-Tenn.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.1544: Accelerating Kids’ Access to Care Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3089: Accelerating Kids’ Access to Care Act

Sponsor: Katherine Clark (D-Mass.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.2666: Medicaid VBPs for Patients Act

Sponsor: Brett Guthrie (R-Ky.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
Jeremy Allen Health Policy Advisor, Rep. Bilirakis; Health Policy Coordinator, House Energy and Commerce Committee
Kate McAuliffe n/a
Kathleen McAuliffe n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Amendment
Q1 Report
Q4 Report
Q3 Report
Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page